

INDEX

Page numbers in **boldface** type indicate major discussions. Letters after page numbers refer to the following: c = case study; f = figure; r = reference; t = table.

A

- AAN (American Academy of Neurology), 600, 652, 685
 practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710
- Absence epilepsy, 581t
 antiepileptic drugs for, 645, 647
 childhood, 575, 587t, 588, 591f, 660c
 classification and characterization of, 593t
 EEG in, 674t
 self-limited, 594
 treatment choices for, 674t–675t
 dietary therapy for, 759, 765r
 early-onset, 579t, 589t
 juvenile, 575, 587t, 590, 591f
 EEG in, 674t
 treatment choices for, 674t–675t
 myoclonic, 578, 581t, 587t, 591f
 with perioral myoclonia, 606c–607c, 606f
 triggered by phenobarbital, 645
- Acetazolamide
 for catamenial epilepsy, 699
 use in children, 662t–663t
- N*-Acetylaspartate (NAA), 640, 734
- ACTH. *See* Adrenocorticotrophic hormone
- Adenylosuccinate lyase deficiency, 579t
- Adolescent-onset epilepsies, 588t, 590, 591f
- Adrenocorticotrophic hormone (ACTH)
 efficacy compared with ketogenic diet, 762, 766r
 for infantile spasms, 577c, 679
 use in children, 662t–663t
- Adult-onset epilepsies, 588t, 590
- AEDs. *See* Antiepileptic drugs
- AES (American Epilepsy Society), practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710
- Age at seizure onset, 580, **586t–587t**, 597r, 674t
- Agoraphobia, 726
- Akinetic seizures, 584t
- Alcohol withdrawal, status epilepticus due to, 769t
- Alper syndrome, 579t
- Ambulatory EEG monitoring, 619, 622r
- American Academy of Neurology (AAN), 600, 652, 685
 practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710
- American Academy of Pediatrics, 797
- American Epilepsy Society (AES), practice parameter for antiepileptic drug use in pregnancy, 703, 706, 707–708, 710
- American Society of Human Genetics, 796
- γ -Aminobutyric acid (GABA), 599
- Amiodarone, interaction with antiepileptic drugs, 652
- Amobarbital, 734
- Amygdalohippocampectomy, 735
- Anti-NMDA receptor antibody encephalitis, 592c–593c, 592f, 596r, 597r
- Antiarrhythmic drugs, interaction with antiepileptic drugs, 652
- Antidepressants
 for anxiety disorders, 691
 for depression, 689–690
 interaction with antiepileptic drugs, 652
- Antiepileptic drugs (AEDs), **643–654**, 654r–655r.
See also specific drugs
 for absence seizures, 645, 647
 in children, 593t, 660c
 adverse effects of, 643, **646t**
 in children, 663t, 665t, 667, 669t, 671t, **672**
 depression, 652, 689, 690c
 documenting discussions with patients about, 802, 803t
 with drug combinations, 648–649, 649t, 672–673
 educating patients about, 802–804
 HLA-B*1502 marker to identify patients at risk for, 672
 idiopathic reactions, 804
 impact on health-related quality of life, 693
 monitoring for, **801–804**, 801c, 804f–805f
 osteopenia/osteoporosis, 652
 psychosis, 691
 suicidality, 688–689
 teratogenicity, 652, 653c, 702, **703–707**, 703t
 weight gain, 650
- in benign epilepsy with centrotemporal spikes, 593t
- during breast-feeding, 684–685, 694r, 705c
- broad-spectrum, 645, 647, 648t
- for children, **660–673**, 680r–681r
 in absence epilepsy, 593t, 660c
 adherence to, 673
 adjusting medications based on seizure timing, 672
 cognitive effects of, 684–685
 discontinuation of, 673
 dosing of, 663t, 665t, 667t, 669t, 671t
 goals of, 661
 indications for, 660–661
 medication selection and management of, 661, **662t–671t**
 polypharmacy and drug interactions with, 672–673
 side effects and monitoring of, 663t, 665t, 667t, 669t, 671t, **672**
 in specific epilepsy syndromes, 674t–675t
 tracking response to, 672
 cognitive effects of, **683–685**
 in adults, 683–684

in children, 684–685
 in unborn child, 685, 686c
 continuation after epilepsy surgery, 740
 discontinuation of, 650, 673
 dosage of, 784t, 786t, 788t
 in Dravet syndrome, 593t
 drug interactions with, 652, 654r, 672–673
 efficacy and tolerability of, 643, 648
 in epilepsy with hypothalamic hamartoma, 593t
 hypersensitivity to, 650
 for infantile spasms, 577c
 informed consent for use of, 802
 for juvenile myoclonic epilepsy, 647c
 mechanisms of action and metabolism of, 644t–645t
 mechanisms of action of, 784t, 786t, 788t
 mood-stabilizing effects of, 652
 narrow-spectrum, 645, 648t
 for patients with specific health issues, 650, 652, 778
 chronic illness, 652
 obesity, 650
 psychiatric disorders, 652
 renal or hepatic disease, 650, 652
 pharmacokinetics of, 785t, 787t, 789t
 in pregnancy, 652–653, 653c, 655r, 685, 686c, 702–711, 713r–714r
 neonatal complications of, 708–709
 neurodevelopmental effects of, 685, 686c, 694r, 707–708, 709f
 pharmacokinetics of, 709–711, 710t
 teratogenicity of, 652, 653c, 702, 703–707, 703t
 monotherapies, 703–706, 705c, 706f, 707t
 polytherapy, 706–707
 resistance to, 595, 730–731, 743–744
 response to, 595
 selection of, 643–650
 for children, 661, 662t–671t
 determining adequate number of drugs, 650, 651c
 for elderly people, 653–654
 by epilepsy syndrome, 645, 647
 for initial therapy, 647–648
 use of add-on drugs, 648–650, 649t
 standard of care and use of, 802
 in status epilepticus, 770c, 775c, 781t, 783f, 784t–789t, 793r–794r
 for diagnosis of nonconvulsive status epilepticus, 770, 777t
 use in women, 652–653
 in West syndrome, 593t
 Antifungals, interaction with antiepileptic drugs, 652
 Antipsychotics, 692c
 interaction with antiepileptic drugs, 652
 for psychosis, 691
 Antiretroviral agents, interaction with antiepileptic drugs, 652
 Anxiety disorders, 691, 696r
 antiepileptic drug-induced, 652
 depression and, 691, 726
 impact on health-related quality of life, 693
 psychogenic nonepileptic events or episodes and, 726
 Arteriovenous malformations, 579t, 737
 Astrocytoma, resection of, 736
 Atonic seizures, 581t, 584t
 Auras, 585t
 Autoimmune encephalopathies, 600
 Autoimmune/inflammatory processes, 573, 580t, 587t
 Automatisms, 585t, 627c
 Autonomic ictal features, 585t–586t
 Autosomal dominant epilepsy with auditory features (autosomal dominant lateral temporal lobe epilepsy), 579t, 587t
 Autosomal dominant nocturnal frontal lobe epilepsy, 579t, 587t
 Azathioprine, 679

B

Balloon cells, in focal cortical dysplasias, 631, 633t
 Barbiturates. *See also specific drugs*
 adverse effects of, 646t
 cognitive effects of, 684
 Beck Depression Inventory, 687, 688, 689, 752
 Benign epilepsy with centrotemporal spikes, 587t, 588, 591f
 classification and characterization of, 593t
 EEG in, 600, 605f
 Benign familial infantile epilepsy, 586t, 591f
 Benign familial neonatal epilepsy, 579t, 586t, 589t, 591f
 Benign infantile epilepsy, 586t
 Benign neonatal seizures, 588t
 Benign rolandic epilepsy
 EEG in, 605f, 674t
 treatment choices for, 674t–675t
 Benzodiazepines, 692c. *See also specific drugs*
 adverse effects of, 785t
 for anxiety disorders, 691
 as broad-spectrum agents, 648t
 cognitive effects of, 684
 mechanism of action of, 784t
 pharmacokinetics of, 785t
 for psychosis, 691
 in status epilepticus, 770c, 776–778, 781t, 783f, 784t–787t
 for diagnosis of nonconvulsive status epilepticus, 777t
 use in children, 662t–665t
 Bilaterally independent periodic lateralizing discharges (BIPLDs) on EEG, 613, 613t, 614f
 Birth defects, antiepileptic drug-induced, 652, 654r, 702, 703–707, 703t
 monotherapies, 703–706, 705c, 706f, 707t
 polytherapy, 706–707
 Bone mineral density, antiepileptic drug effects on, 652, 711–712, 711c, 714r

- Brain abscess, 580t
- Brain neoplasms
 antineoplastic drugs for patients with, 778
 epilepsy due to, 579t, 580t, 587t
 neuroimaging of, 637–638, 637f–639f, 639t
 resection of, 736–737, 736f
 status epilepticus due to, 769t
- Brainstem mechanisms, 573–574
- Breast-feeding and antiepileptic drugs, 684–685, 694r, 705c
- Breath-holding spells, 715
- Bromides
 adverse effects of, 646t
 mechanism of action and metabolism of, 644t
- Bupropion, 600, 690
- Buspironone, 691
- C**
- Calcium channel blockers, interaction with antiepileptic drugs, 652
- Carbamazepine, 606c, 692c
 adverse effects of, 646t, 802, 804
 hematologic effects, 804
 HLA-B*1502 allele and risk for Stevens-Johnson syndrome, 672, 804, 805r
 weight gain, 650
 during breast-feeding, 685
 cognitive effects of, 684, 693r
 combined with other antiepileptic drugs, 649
 lacosamide, 649
 lamotrigine, 649
 phenytoin, 649, 649t
 drug interactions with, 652
 efficacy of, 648
 for epilepsy with hippocampal sclerosis, 627c
 hypersensitivity to, 650
 indications for, 647
 mechanism of action and metabolism of, 644t
 mood-stabilizing effects of, 652
 as narrow-spectrum agent, 645, 648t
 in pregnancy, 652, 685, 704, 705c
 neurodevelopmental effects of, 707, 708, 709f
 pharmacokinetics of, 710, 710t
 teratogenicity of, 652, 704, 705c, 706–707, 706f, 707t
 use in children, 662t–663t
- Cardiac arrest, treatment of refractory and myoclonic status epilepticus after, 791
- Cardiac disease, antiepileptic drugs in, 778
- Cardiac malformations, antiepileptic drug-induced, 652, 703, 703t, 704, 706
- Case studies
 absence seizures with perioral myoclonia, 606c–607c
 anti-NMDA receptor antibody encephalitis, 592c–593c
 antiepileptic drug effects on bone mineral density, 711c
 antiepileptic drugs in pregnancy, 653c, 686c, 705c–706c
 childhood absence epilepsy, 660c
 convulsive status epilepticus, 770c
 diagnostic coding, 809c–812c
 dietary therapies, 761c
 Dravet syndrome, 576c
 epileptic seizures and neurocardiogenic syncope, 615c–618c
 ethics of genetic testing in children with epilepsy, 795c
 infantile spasms, 577c
 levetiracetam in juvenile myoclonic epilepsy, 647c
 mesial temporal lobe epilepsy and hippocampal sclerosis, 627c
 monitoring and antiepileptic drug safety, 801c
 mood effects of antiepileptic drugs, 690c
 nonconvulsive status epilepticus, 775c
 diagnosis in critically ill patient, 778c
 psychogenic nonepileptic events or episodes, 721c
 psychosis and epilepsy, 692c
 surgical treatment
 contraindications to, 732c
 for focal cortical dysplasia, 738c–739c
 in mesial temporal epilepsy, 736c
 use of multiple antiepileptic drugs, 651c
 vagus nerve stimulation, 747c
- Catamenial epilepsy, 697–700, 712r
 criteria for, 698
 definition of, 697
 patterns of, 698, 699f
 treatment options for, 698–700
- Cataplexy, 715
- Cavernous malformations, 579t, 737
- CDC (Centers for Disease Control and Prevention), 796
- Cefepime, EEG abnormalities induced by, 600
- Center for Epidemiologic Study Depression Screen, 688, 689
- Center for Medicare and Medicaid Services (CMS), 806
- Centers for Disease Control and Prevention (CDC), 796
- Cephalic auras, 585t
- Cerebral infarction, 579t
- Cerebrovascular disease, 579t
- Channelopathies, 573, 574, 579t
- Chemotherapeutic agents, interaction with antiepileptic drugs, 652
- Childbirth rates, 701–702
- Childhood epilepsy, 586t–587t, 656–680, 680r–681r
 absence epilepsy, 575, 587t, 588, 591f, 593t, 660c
 classification and characterization of, 593t
 EEG in, 674t
 self-limited, 594
 treatment choices for, 674t–675t

antiepileptic drug therapy for, 660–673
 adherence to, 673
 adjusting medications based on seizure timing, 672
 cognitive effects of, 684–685
 discontinuation of, 673
 dosing of, 663t, 665t, 667t, 669t, 671t
 goals of, 661
 indications for, 660–661
 medication selection and management of, 661, 662t–671t
 polypharmacy and drug interactions with, 672–673
 side effects and monitoring of, 663t, 665t, 667t, 669t, 671t, 672
 in specific epilepsy syndromes, 674t–675t
 tracking response to, 672
 chances of seizure recurrence in, 660–661
 diagnostic evaluation of, 656
 differentiation from psychogenic nonepileptic events or episodes, 725
 distribution of types of, 588, 590, 591f
 ethics of genetic testing in, 795–799, 795c, 799r–800r
 nonpharmacologic treatment of, 673–680
 ketogenic diet, 678–679
 other options, 679–680
 for pyridoxine-dependent seizures, 679
 steroids and immunomodulatory therapy, 679
 surgery, 673, 676–678
 candidates for, 673, 676
 estimating potential deficits after, 676, 677
 outcome of, 677–678
 preoperative workup for, 676–677, 676f, 677f
 procedures for, 677
 vagus nerve stimulation, 678
 seizure classification and syndromes of, 657, 660
 seizure confirmation in, 656–657, 660c
 nonepileptic paroxysmal events mimicking epileptic seizures, 658t–659t
 status epilepticus, 767
 etiologies of, 769t
 Citalopram, 690
 Classification of seizures and epilepsy, 571–595, 595r–597r
 in children, 657, 660
 as diagnosis, 572
 vs. diagnosis, 571, 572
 diagnostic targets for, 578–594
 epilepsies and epilepsy diagnosis, 580–594, 586t–589t
 etiology, 578, 579t–580t
 seizure types, 578–580, 581t, 582t, 583f, 584t–586t
 goals of, 571
 history of, 571–572
 meaning of, 572
 as organizational system, 572
 updated terminology and concept for, 571, 573–576
 epileptic encephalopathy, 594
 etiologies/causes, 571, 573, 574t
 mode of onset and presentation, 571, 573–576, 575t
 pharmacoresponsive or pharmacoresistant epilepsy, 595
 self-limited epilepsy, 594–595
 Cleft lip/palate, antiepileptic drug–induced, 652, 703, 703t, 704, 706
 Clobazam
 for catamenial epilepsy, 699
 use in children, 662t–663t
 Clonazepam, 692c
 teratogenicity of, 707t
 use in children, 662t–663t
 Clonic seizures, 581t, 584t
 Clozapine, EEG abnormalities induced by, 600
 CMS (Center for Medicare and Medicaid Services), 806
 Cobalamin C deficiency, 579t
 Coding, diagnostic, 806–809, 809c–812c, 812r
 Cognitive behavioral therapy, 690–691
 Cognitive impairment in epilepsy, 682–687, 693r–694r, 730
 antiepileptic drugs and, 683–685
 in adults, 683–684
 in children, 684–685
 in unborn child, 685, 686c, 707–708
 before first seizure, 682
 neuropsychological and pathologic substrates of, 682–683
 psychosocial factors and, 687
 seizure effects and, 683
 temporal lobe epilepsy surgery and, 685–686, 732
 vagus nerve stimulation and, 686–687
 Computed tomography (CT), 624
 of low-grade tumors, 638f, 639f
 in status epilepticus, 774, 775f, 780t
 in tuberous sclerosis, 638
 Congenital malformations, antiepileptic drug–induced, 652, 654r, 702, 703–707, 703t
 monotherapies, 703–706, 705c, 706f, 707t
 polytherapy, 706–707
 Contraception, 702, 714r
 Conversion disorder, 722–723, 725
 Corpus callosotomy, 738–739
 Cortical development, malformations of, 579t, 587t, 596r
 neuroimaging of, 623, 631–637, 641r–642r
 focal cortical dysplasias, 623, 625, 628t, 629f, 630, 630f, 631–632, 632f, 633t
 hemimegalencephaly, 636f, 637
 lissencephaly-agyria-pachygyria, 635f, 636
 periventricular nodular heterotopia, 635f, 636, 636f
 polymicrogyria, 634–636, 634f, 635f
 schizencephaly, 633–634, 634f

subcortical laminar heterotopia, 635f, 636
 Corticosteroids, 679, 681r
 Counseling, genetic, 578, 797–799, 799r–800r
CPT (Current Procedural Terminology) codes, 807–808
 useful internet tips for coding, 808
 CT. *See* Computed tomography
Current Procedural Terminology (CPT) codes, 807–808
 useful internet tips for coding, 808
 Cyclophosphamide, 679

D

Dacrystic seizures, 585t
 Deep brain stimulation of anterior nucleus of thalamus, 743, 746–749, 754r
 advantages and disadvantages of, 753
 adverse effects of, 749
 cognitive effects of, 687, 749
 efficacy of, 749
 evidence for, 747
 multicenter randomized controlled trial of, 748–749
 procedure for, 747–748, 748f
 responder rate for, 752
 Dentatorubral-pallidoluyisan atrophy, 579t
 Depression, 687–691, 694r–696r
 antiepileptic drug-induced, 652, 689, 690c, 804
 anxiety disorders and, 691, 726
 features and incidence in epilepsy, 687–688
 impact on health-related quality of life, 692–693
 interictal dysphoric disorder and, 689
 preictal, ictal, and postictal, 689
 psychogenic nonepileptic spells and, 688
 risk factors for, 687
 screening tests for, 688, 689
 subsyndromic, 689
 suicide risk and, 688–689
 treatment of, 689–691
 antidepressants, 689–690
 cognitive behavioral therapy, 690–691
 electroconvulsive therapy, 690
 trigeminal nerve stimulation and, 752
 underdiagnosis and undertreatment of, 688
 vagus nerve stimulation for, 745
 Depth electrodes, intracranial, 620
 Diagnosis of epilepsy, 580–594, 586t–589t
 by adult neurologists, 588
 by age at initial presentation, 580, 586t–587t
 in children, 656
 nonepileptic paroxysmal events mimicking epileptic seizures, 658t–659t
 seizure confirmation, 656–657, 660c
 vs. classification, 571, 572
 EEG in, 598, 600–602, 620r–622r
 correlation with clinical history and imaging studies, 602
 normal variants or benign patterns that may confuse diagnosis, 607–608, 609t, 610f

with photic stimulation or hyperventilation, 601, 602f
 sensitivity and specificity of, 600–601, 601f
 with sleep deprivation, 601
 sources of error, 602
 electroclinical syndromes, 582
 nonsyndromic epilepsies, 589t, 590–591, 591f, 594
 seizure types and, 578–580, 581t, 582t, 583f, 584t–586t

Diagnostic and Statistical Manual of Mental Disorders (DSM), 689, 722–723

Diagnostic coding, 806–809, 809c–812c, 812r

Diazepam, 692c

adverse effects of, 785t

dosage of, 784t

pharmacokinetics of, 785t

for status epilepticus, 776, 781t, 784t–785t

use in children, 664t–665t

Dietary therapies, 756–765, 765r–766r

compared with normal American diet, 758–759, 759t

composition by percentage of kilocalories, 759t

contraindications to, 763–764

dropout rates from, 762–763

history of, 756–757

indications for, 679, 759–760, 761c

ketogenic diet, 678–679, 756–757

low glycemic index treatment, 757, 758, 758t

medium-chain triglyceride diet, 756, 757

modified Atkins diet, 757–758

outcomes of, 760–763

overview of, 757–759

potential mechanisms of action of, 759, 760f

requirements for, 758t

side effects of, 763, 763t

monitoring and management of, 764

in status epilepticus, 790t

trends and future direction of, 764

websites for information on, 765

Diffusion tensor imaging and tractography, 639–640, 642r

Digoxin, interaction with antiepileptic drugs, 652

Discontinuation of antiepileptic drug therapy, 650, 673

Doose syndrome, 589t, 765r

dietary therapy for, 679, 759

Down syndrome, 579t

Dravet syndrome, 573, 576, 576c, 576f, 579t, 586t, 588, 591f, 594

classification and characterization of, 593t

dietary therapy for, 679, 759

EEG in, 576f, 609t, 674t

genetics of, 576c, 589t

pharmacoresistance of, 593t, 595

treatment choices for, 674t–675t

Driving, 647, 687, 709, 724, 803t

Drug interactions with antiepileptic drugs, 652, 654r, 672–673

Drug intoxication, status epilepticus due to, 769t

- Drug-resistant epilepsy, 595, 730–731, 743–744, 754r
 dietary treatment of, 756–765, 765r–766r
 neurostimulation for, 743–754, 754r–755r
 surgery for, 730–740, 740r–742r, 743–744
- DSM (*Diagnostic and Statistical Manual of Mental Disorders*), 689, 722–723
- Dual-energy x-ray absorptiometry (DXA), 711
- DXA (dual-energy x-ray absorptiometry), 711
- Dyscognitive events, 585t
- Dysembryoplastic neuroepithelial tumors, 579t
 neuroimaging of, 638, 639t
 resection of, 736
- Dystonia, 715
- E**
- EEG. *See* Electroencephalography
- Elderly people
 antiepileptic drugs for, 653–654, 655r
 cognitive effects of, 684
 status epilepticus in, 767
- Electroconvulsive therapy
 for depression, 690
 for status epilepticus, 790t
- Electroencephalography (EEG), 598–620, 620r–622r
 abnormal epileptic patterns on, 604–607
 in epileptic encephalopathies, 607, 609t
 focal spikes or sharp waves, 604–605, 605f
 generalized spikes, 605–607, 606c–607c, 606f
 rhythmic temporal delta activity, 607, 608f
 slow spike and wave, 607
- in absence epilepsy
 childhood, 674t
 juvenile, 674t
 with perioral myoclonia, 606c–607c, 606f
- ambulatory, 619
- in anti-NMDA receptor antibody encephalitis, 592c, 592f
- in autoimmune encephalopathies, 600
- in benign epilepsy with centrotemporal spikes, 600
- in benign rolandic epilepsy, 605f, 674t
- continuous EEG monitoring in the ICU, 613, 618–619
- in diagnosis of epilepsy, 598, 600–602
 correlation with clinical history and imaging studies, 602
 with photic stimulation or hyperventilation, 601, 602f
 sensitivity and specificity of, 600–601, 601f
 with sleep deprivation, 601
 sources of error, 602
- in Dravet syndrome, 576f, 609t, 674t
- drug-induced abnormalities on, 600
- in epileptic seizures and neurocardiogenic syncope, 616f–618f
- in epileptic spasms, 582t, 583f
 infantile, 577c, 577f
 history of, 598
- in juvenile myoclonic epilepsy, 601f, 674t, 686c
- in Landau-Kleffner syndrome, 674t
- in Lennox-Gastaut syndrome, 674t
- in metabolic disorders, 600
- in myoclonic seizures, 582t, 583f
- in myoclonic-tonic seizures, 582t, 583f
- nonspecific abnormal nonepileptic patterns on, 602–604, 603t
 diffuse slow activity, 602
 focal slow activity, 602
 focal voltage attenuation, 602
 frontal intermittent rhythmic delta activity, 602, 603f, 604
 triphasic waves, 602, 604, 604f
- normal, in epilepsy, 600
- normal variants or benign patterns on, 607–608, 609t, 610f–612f
 14 and 6 positive spikes, 608
 rhythmic midtemporal theta of drowsiness, 607–608
 6-Hz spike and wave, 608
 subclinical rhythmic electrographic discharges of adults, 608
 wicket spikes, 607, 608
- in Ohtahara syndrome, 607, 609t, 674t
- in Panayiotopoulos syndrome, 674t
- physiologic basis for interictal patterns on, 598–600, 599f
- in preoperative workup, 731, 733f, 734, 739f
 for childhood epilepsy, 676, 676f
- psychogenic nonepileptic seizures on, 619–620
- in status epilepticus, 608–613, 773–774
 continuous EEG monitoring, 618, 622r, 768, 774, 778c, 779f
 convulsive, *Mycoplasma pneumoniae*-associated, 771f
 nonconvulsive, 775f
 periodic patterns, 609, 613, 613t, 614f–615f
 progressive sequence of changes, 608–609, 621r
- in tonic seizures, 582t, 583t
- utility of inpatient video-EEG monitoring, 619–620 (*See also* Video-EEG monitoring)
 invasive monitoring, 620
 scalp EEG monitoring, 619–620
- in West syndrome, 603t, 607, 609t, 674t
- Electromyography (EMG)
 in epileptic spasms, 582t
 in myoclonic seizures, 582t
 in myoclonic-tonic seizures, 582t
 in tonic seizures, 582t
- Encephalitis, 580t
 anti-NMDA receptor antibody, 592c–593c, 592f
- Encephalopathy(ies)
 autoimmune, 600
 epileptic, 594
 with continuous spike-and-wave during sleep, 587t
 EEG in, 607, 609t
 immunomodulatory therapies for, 679

- Hashimoto, 600
 hypoxic-ischemic, 579t, 587t
 mitochondrial encephalopathy, lactic acidosis, and strokelike episodes, 579t
 myoclonic, 586t
 toxic-metabolic, 603t
- Epigastric auras, 585t, 627c
- Epilepsy
 antiepileptic drugs for, 643–654, 654r–655r
 catamenial, 697–700, 712r
 childhood, 586t–587t, 656–680, 680r–681r
 classification of, 571–595, 595r–597r
 cognitive impairment in, 682–687, 693r–694r, 730
 diagnosis of, 580–594, 586t–589t
 diagnostic coding for, 806–809, 809c–812c, 812r
 differentiating nonepileptic behavioral disorders from, 715–727, 727r–729r
 drug-resistant, 595, 730–731, 743–744, 754r
 dietary treatment of, 756–765, 765r–766r
 neurostimulation for, 743–754, 754r–755r
 surgical treatment of, 730–740, 740r–742r, 743–744
 EEG in, 598–620, 620r–622r
 mortality and, 730
 neuroimaging in, 623–641, 641r–642r
 pharmacoresponsive or pharmacoresistant, 595
 psychiatric disorders and, 687–691, 694r–696r
 self-limited, 594–595
 in women, 697–712, 712r–714r
- Epilepsy of infancy with migrating focal seizures, 586t
- Epilepsy with generalized tonic-clonic seizures alone, 587t
- Epileptic encephalopathy, 594
 with continuous spike-and-wave during sleep, 587t
 EEG in, 607, 609t
 immunomodulatory therapies for, 679
- Epileptic spasms, 578, 581t, 584t, 596r
 differential diagnosis of, 582t
 EEG in, 577c, 577f, 582t, 583f
 infantile, 577c, 577f, 578, 596r (*See also* West syndrome)
 adrenocorticotrophic hormone for, 577c, 679
 dietary therapy for, 679, 759
 due to tuberous sclerosis, vigabatrin for, 645
- Episodic ataxia types 1 and 2, 579t
- Eslicarbazepine, 648t
- Estrogens
 interactions between epilepsy, antiepileptic drugs and, 697, 698f
 during menstrual cycle, 698, 699f
 during perimenopausal transition, 700
- Ethics of genetic testing in children with epilepsy, 795–799, 795c, 799r–800r
- Ethosuximide
 for absence seizures, 645
 in children, 660c
 adverse effects of, 646t
 mechanism of action and metabolism of, 644t
 as narrow-spectrum agent, 648t
 pharmacokinetics in pregnancy, 710t
 use in children, 660c, 664t–665t
- Etiologies/causes of epilepsy, 578, 579t–580t
 genetic, 571, 573, 574t, 579t
 structural-metabolic, 571, 573, 574t
 unknown, 571, 573, 574t
 updated terminology and concepts for, 571, 573, 574t
- Etomidate
 adverse effects of, 787t
 dosage of, 786t
 pharmacokinetics of, 787t
 for status epilepticus, 786t–787t
- European and International Registry of Antiepileptic Drugs in Pregnancy (EURAP), 705c
- European Federation of Neurological Societies, 772
- European Surveillance of Congenital Anomalies (EUROCAT), 704
- Eyelid myoclonia, 578, 581t
- Ezogabine
 adverse effects of, 646t
 weight gain, 650
 indications for, 647
 mechanism of action and metabolism of, 645t
 spectrum of activity of, 648t
 use in children, 664t–665t
- F**
- Factitious disorders, 722–723
- Familial focal epilepsy with variable foci, 587t
- Febrile infection-related epilepsy syndrome (FIRES), ketogenic diet for, 679
- Febrile seizures, 586t, 588t, 594
 generalized epilepsy with, 579t, 589t, 596r
 status epilepticus due to, 769t
- Felbamate
 adverse effects of, 646t, 789t, 804, 805r
 anxiety or insomnia, 652
 as broad-spectrum agent, 645, 648t
 dosage of, 788t
 in hepatic disease, 650
 mechanism of action and metabolism of, 644t
 pharmacokinetics of, 789t
 for status epilepticus, 788t–789t
 use in children, 664t–665t
- Fertility, 700, 701–702. *See also* Pregnancy
- Fetal effects of maternal seizures, 709
- FIRDA (frontal intermittent rhythmic delta activity) on EEG, 602, 603f, 603t, 604
- FIRES (febrile infection-related epilepsy syndrome), ketogenic diet for, 679
- Focal cortical dysplasia, 577c, 641r, 731
 balloon cells in, 631, 633t
 classification of, 633t

neuroimaging of, 623, 625, 628t, 629f, 630, 630f, 631–632, 632f, 633t, 731
surgery for, 737, 737f–739f, 738c–739c
Focal seizures, 571, 573–576, 575t, 578, 581t
Follicle-stimulating hormone (FSH), 700
Fosphenytoin
adverse effects of, 785t
dosage of, 784t
pharmacokinetics of, 785t
for status epilepticus, 778, 781t, 783f,
784t–785t
drug trial for diagnosis of nonconvulsive
status epilepticus, 777t
14 and 6 positive spikes on EEG, 608, 609t, 612f
Frontal intermittent rhythmic delta activity
(FIRDA) on EEG, 602, 603f, 603t, 604
FSH (follicle-stimulating hormone), 700
Fukuyama congenital dystrophy, 579t

G

GABA (γ -aminobutyric acid), 599
Gabapentin, 692c
adverse effects of, 646t, 787t
teratogenicity, 707t
weight gain, 650
cognitive effects of, 684, 693r, 694r
dosage of, 786t
efficacy of, 648
hypersensitivity to, 650
mechanism of action and metabolism of, 644t
as narrow-spectrum agent, 645, 648t
pharmacokinetics of, 787t
in renal disease, 650
for status epilepticus, **786t–787t**
use in children, 664t–665t
Gangliogliomas, 579t
neuroimaging of, 637f, 638
resection of, 736, 736f
Gaucher disease, 579t
Gelastic seizures with hypothalamic hamartoma,
587t, 588, 590f
Generalized periodic discharges (GPDs) on EEG,
613, 613t, 615f
Generalized seizures, 571, 573–576, 575t, 578, 581t
Genetic epilepsies, 571, 573, 574t, 576, 578, **579t**,
596r
Dravet syndrome, 573, 576, 576c, 576f
specific genes first associated with one epilepsy
syndrome then found to be associated with a
different epilepsy syndrome, 589t
Genetic testing in children with epilepsy,
795–799, 795c, 799r–800r
ACCE model for decision making about, 796
diagnostic, 796–797
genetic counseling before, 797–799
Gestural seizures, 585t
Gliomas, 579t, 637f–638f, 638
Glucose transporter type 1 (*GLUT1*) deficiency
syndrome, 579t, 589t, 596r, 679
dietary therapy for, 678–679, 759

Gonadotropin-releasing hormone (GnRH), 700
GPDs (generalized periodic discharges) on EEG,
613, 613t, 615f

H

Hallucinations, 692c, 735
Hashimoto encephalopathy, 600
Hemiconvulsions, 576c, 578
Hemimegalencephaly, 636f, 637, 738
Hemispherectomy, 737, 738
Hemispheric syndromes, 738
Hepatic disease, antiepileptic drugs in, 650, 652,
778
Hippocampal resection, 735
Hippocampal sclerosis
mesial temporal lobe epilepsy with, 587t, 625f,
626f, 627c, 627t, 628, 631t
presurgical imaging evaluation of, 628, 631t
Hippocrates, 756, 765r
HIV infection, 580t
*HLA-B*1502* allele and risk for Stevens-Johnson
syndrome, 672, 804, 805r
Hormonal contraceptives, interaction with
antiepileptic drugs, 652, 702
HRQOL. *See* Quality of life, health-related
Hyperreflexia, 573–574, 586t, 596r
Hyperkinetic/hypermotor seizures, 585t
Hyperventilation, EEG with, 601, 621r
Hypomotor/behavioral arrest seizures, 584t
Hypospadias, antiepileptic drug-induced, 704,
706
Hypothalamic hamartoma with epilepsy, 579t,
593t
gelastic seizures, 587t, 588, 590f
surgical treatment of, 737
vagus nerve stimulation and, 678
Hypothalamic hypogonadism, 700
Hypothalamic-pituitary-ovarian axis, 697, 698f
Hypothermia, for status epilepticus, 790t
Hypoxic-ischemic encephalopathy, 579t, 587t
Hypsarrhythmia, infantile spasms with, 577c, 577f,
607

I

ICD. See International Classification of Diseases
IDD (interictal dysphoric disorder), 689
IDDI (Interictal Dysphoric Disorder Inventory),
689
ILAE (International League Against Epilepsy), 571,
572, 595r, 596r, 600, 619, 657, 807
Immune therapies
for childhood epilepsy, 679
for status epilepticus, **788t–789t**, 790
Immunosuppressive agents, interaction with
antiepileptic drugs, 652
Infantile epilepsies, 579t, 586t
dietary therapy for, 759
Dravet syndrome, 576c
hyperreflexia, 573–574

Infantile spasms, 577c, 577f, 578, 596r. *See also* West syndrome
 adrenocorticotrophic hormone for, 577c, 679
 dietary therapy for, 679, 759
 due to tuberous sclerosis, vigabatrin for, 645
 Infectious etiologies of epilepsy, 580t, 587t
 status epilepticus due to, 769t, 770c
 Infertility, 700, 701–702
 Informed consent, 802
 Insomnia, antiepileptic drug-induced, 652
 Interictal dysphoric disorder (IDD), 689
 Interictal Dysphoric Disorder Inventory (IDDI), 689
International Classification of Diseases (ICD), 571, 572, 723
 diagnostic code set, 806–809
 case studies of use of, 809c–812c
 useful internet tips for use of, 808
 structures of *ICD-9-CM* and *ICD-10*, 806–807
 International League Against Epilepsy (ILAE), 571, 572, 595r, 596r, 600, 619, 657, 807
 Intracranial depth electrodes, 620
 Intrauterine device (IUD), 702
 Intravenous immunoglobulin
 for childhood epilepsy, 679
 for status epilepticus, 788t–789t
 IUD (intrauterine device), 702

J

Juvenile absence epilepsy, 575, 587t, 590, 591f
 EEG in, 674t
 treatment choices for, 674t–675t
 Juvenile myoclonic epilepsy, 575, 579t, 587t, 590, 591f
 EEG in, 601f, 674t, 686c
 levetiracetam for, 647c
 outcome of, 594–595, 597r
 pharmacoresponsiveness of, 595
 treatment choices for, 674t–675t

K

KCNQ2 gene mutations, 589t, 596r
 Kerala Registry of Epilepsy and Pregnancy, 701
 Ketamine
 adverse effects of, 787t
 dosage of, 786t
 pharmacokinetics of, 787t
 for status epilepticus, 770c, 786t–787t, 790
 Ketogenic diet, 678–679, 756–765, 765r–766r
 composition by percentage of kilocalories, 759t
 contraindications to, 763–764
 efficacy of, 762
 fats in, 757
 history of, 756–757 (*See also* Dietary therapies)
 indications for, 679, 759–760, 761c
 initiation of, 757
 overview of, 757
 potential mechanisms of action of, 759, 760f
 requirements for, 758t

side effects of, 763, 763t
 monitoring and management of, 764
 for status epilepticus, 790t
 trends and future direction of, 764
 vagus nerve stimulation and, 759
 websites for information on, 765
 Krabbe disease, 579t

L

Laboratory testing in status epilepticus, 772–773, 780t
 Lacosamide
 adverse effects of, 646t, 785t
 combined with other antiepileptic drugs, 649
 dosage of, 784t
 indications for, 647
 mechanism of action and metabolism of, 645t
 pharmacokinetics of, 785t
 spectrum of activity of, 648t
 for status epilepticus, 778, 782, 784t–785t
 drug trial for diagnosis of nonconvulsive status epilepticus, 777t
 use in children, 664t–665t
 Lafora body disease, 579t
 Lamotrigine, 606c, 692c, 801c
 adverse effects of, 646t
 anxiety or insomnia, 652
 during breast-feeding, 685
 as broad-spectrum agent, 645, 648t
 cognitive effects of, 684
 combined with other antiepileptic drugs, 649
 lacosamide, 649
 valproate, 649, 649t, 653c
 efficacy and tolerability of, 643, 648
 indications for, 645, 647, 647c
 mechanism of action and metabolism of, 644t
 mood-stabilizing effects of, 652
 for patients with specific health issues, 650
 in pregnancy, 652, 653c, 655r, 685, 704, 705c, 714r
 neurodevelopmental effects of, 708, 709f
 pharmacokinetics of, 710–711, 710t
 teratogenicity of, 652, 704, 705c, 706, 706f, 707t
 use in children, 666t–667t
 Landau-Kleffner syndrome, 587t, 591f, 594
 EEG in, 607, 609t, 674t
 immunomodulatory therapies for, 679
 treatment choices for, 674t–675t
 vagus nerve stimulation, 678
 Leigh syndrome, 579t
 Lennox-Gastaut syndrome, 576, 579t, 587t, 594
 EEG in, 603t, 607, 609t, 674t
 treatment choices for, 674t–675t
 dietary therapy, 759
 rufinamide, 645
 vagus nerve stimulation, 678
 worsening by phenobarbital, 645
 Levetiracetam, 606c
 adverse effects of, 646t, 785t, 804

- behavioral effects, 652
 psychosis, 691
 during breast-feeding, 705c
 as broad-spectrum agent, 645, 648t
 cognitive effects of, 684
 dosage of, 784t
 efficacy and tolerability of, 643, 648
 hypersensitivity to, 650
 indications for, 645
 in juvenile myoclonic epilepsy, 647c
 mechanism of action and metabolism of, 644t
 pharmacokinetics of, 785t
 in pregnancy, 705c
 pharmacokinetics of, 710, 710t
 teratogenicity of, 707t
 in renal disease, 650
 for status epilepticus, 770c, 778, 781t, 782, **784t–785t**
 drug trial for diagnosis of nonconvulsive status epilepticus, 777t
 use in children, 666t–667t
 Levonorgestrel intrauterine device, 702
 LH (luteinizing hormone), 700
 Lidocaine
 adverse effects of, 787t
 dosage of, 786t
 pharmacokinetics of, 787t
 for status epilepticus, **786t–787t**
 Lipid-lowering agents, interaction with antiepileptic drugs, 652
 Lissencephaly, 579t
 Lissencephaly-agyria-pachygyria, 635f, 636
 Lithium, EEG abnormalities induced by, 600
 Lorazepam
 adverse effects of, 785t
 dosage of, 784t
 pharmacokinetics of, 785t
 for status epilepticus, 770c, 775c, **776–777**, 781t, 783f, **784t–785t**
 use in children, 666t–667t
 Low glycemic index treatment, 757, 758t
 composition by percentage of kilocalories, 759t
 efficacy of, 762
 overview of, 758
 sample diet for, 758t
 Lumbar puncture, 776, 780t
 Luteinizing hormone (LH), 700
- M**
- Magnesium sulfate
 adverse effects of, 789t
 dosage of, 788t
 pharmacokinetics of, 789t
 for status epilepticus, **788t–789t**
 Magnetic resonance imaging (MRI), 597t, 623, **624–626**, 641r–642r
 in anti-NMDA receptor antibody encephalitis, 592f
 of deep brain stimulation lead placement, 748f
 in Dravet syndrome, 576c
 functional, for localization of seizure focus, 735
 in gelastic seizures with hypothalamic hamartoma, 590f
 indications for, 624
 in infantile spasms, 577c, 577f
 of low-grade tumors, 637f–639f
 in malformations of cortical development, **631–637**
 focal cortical dysplasias, 623, 625, 628t, 629f, 630, 630f, **631–632**, 632f, 633t, 731, 738f
 hemimegalencephaly, 636f, 637
 lissencephaly-agyria-pachygyria, 635f, 636
 periventricular nodular heterotopia, 635f, 636, 636f
 polymicrogyria, 634–636, 634f, 635f
 schizencephaly, 633–634, 634f
 subcortical laminar heterotopia, 635f, 636
 in mesial temporal lobe epilepsy, 623, 625, **626–628**
 with hippocampal sclerosis, 625f, 626f, 627c, 627t, 628, 631t, 642r
 of mesial temporal sclerosis, 736c, 736f
 in neocortical epilepsies, 623, 625, **628–631**, 628t, 629f, 630f
 normal, identifying seizure focus in patients with, 731, 732c
 in pharmacoresistant epilepsy with focal seizures arising from left temporal lobe, 590f
 in preoperative workup, 731
 for childhood epilepsy, 676, 676f
 protocols for, 623, 624–626, 629f, 630f
 in Rasmussen encephalitis, 590f, 624, 639
 in status epilepticus, 774, 780t
 in temporal lobe epilepsy, 683
 in tuberous sclerosis, **637–638**, 637f
 volumetric, of cognitive function, 683
 Magnetic resonance spectroscopy (MRS), 623, **640**, 642r
 of hippocampal sclerosis, 631t
 in mesial temporal lobe epilepsy, 640
 Magnetoencephalography (MEG), 676
 Major depressive disorder (MDD). *See* Depression
 Malaria, 580t
 Malingering, 722–723
 Mammalian target of rapamycin (mTOR), 578
 Manual/pedal seizures, 585t
 MDD (major depressive disorder). *See* Depression
 Medium-chain triglyceride diet, 756, 757. *See also* Dietary therapies
 Medroxyprogesterone acetate
 for catamenial epilepsy, 699
 intramuscular, for contraception, 702
 MEG (magnetoencephalography), 676
 Memory deficits. *See* Cognitive impairment
 Meningioma, 579t, 736
 Meningitis, 580t
 Menopause, 700
 Menstrual cycle–related epilepsy, 697–700. *See also* Catamenial epilepsy

- Mental retardation, 623
 epilepsy in females with, 576, 586t, 589t, 595
- Mesial temporal lobe epilepsy, 588
 familial, 597r
 with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
 magnetic resonance spectroscopy in, 640
 with mesial temporal sclerosis, 735, 736c
 MRI in, 623, 625, 625f, 626f, 627c, 627t
 positron emission tomography in, 640
 single-photon emission computed tomography in, 641
 surgical treatment of, 730, 735, 736c
- Mesial temporal lobe epilepsy (MTLE), 588
 familial, 597r
 with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
 presurgical imaging evaluation of, 628
 magnetic resonance spectroscopy in, 640
 MRI in, 623, 625, 625f, 626–628, 626f, 627c, 627t
 positron emission tomography in, 640
 single-photon emission computed tomography in, 640
- Mesial temporal sclerosis (MTS), 735, 736c, 738
- Metabolic disorders
 EEG in, 600
 status epilepticus due to, 769t
- Methsuximide, use in children, 666t–667t
- Methylprednisolone, for status epilepticus, 788t–789t
- Midazolam
 adverse effects of, 785t, 787t
 dosage of, 784t, 786t
 pharmacokinetics of, 785t, 787t
 for status epilepticus, 770c, 777, 781t, 783f, 784t–785t, 786t–787t
 drug trial for diagnosis of nonconvulsive status epilepticus, 777t
 refractory, 788
- Migraine, complicated, 715
- Mimetic seizures, 585t
- Minnesota Multiphasic Personality Inventory (MMPI), 723
- Misdiagnosis of epilepsy, 715, 716
- Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes, 579t
- MMPI (Minnesota Multiphasic Personality Inventory), 723
- Mode of onset of seizures, 573–576, 575t, 573571
- Modified Atkins diet, 757. *See also* Dietary therapies
 composition by percentage of kilocalories, 759t
 efficacy of, 762
 overview of, 757–758
 requirements for, 758t
- Monoamine oxidase inhibitors, 690
- Mortality rate, 730
- Movement disorders, paroxysmal, 715
- MRI. *See* Magnetic resonance imaging
- MRS. *See* Magnetic resonance spectroscopy
- MTLE. *See* Mesial temporal lobe epilepsy
- mTOR (mammalian target of rapamycin), 578
- MTS (mesial temporal sclerosis), 735, 736c, 738
- Multiple sclerosis, 722
- Mycoplasma pneumoniae*-associated status epilepticus, 770c, 771f
- Myoclonic absence epilepsy, 578, 581t, 587t, 591f
- Myoclonic-astatic epilepsy, 589t, 765r
 dietary therapy for, 679, 759
- Myoclonic-atonic seizures, 578, 581t, 586t, 591f
- Myoclonic encephalopathy, 586t
- Myoclonic epilepsy, 597r
 of infancy, 579t, 586t, 597r (*See also* Dravet syndrome)
 juvenile, 575, 579t, 587t, 590, 591f
 EEG in, 601f, 674t, 686c
 levetiracetam for, 647c
 outcome of, 594–595, 597r
 pharmacoresponsiveness of, 595
 treatment choices for, 674t–675t
 levetiracetam for, 645, 647c
 progressive, 579t, 587t
 EEG in, 607, 609t
 with ragged red fibers, 579t
 worsening by phenobarbital, 645
- Myoclonic seizures, 581t, 584t
 differential diagnosis of, 582t
 EEG in, 582t, 583f
 negative, 584t
- Myoclonic status epilepticus after cardiac arrest, 791
- Myoclonic-tonic seizures, 578, 581t
 differential diagnosis of, 582t
 EEG in, 582t, 583f
- Mysoline, depression induced by, 652

N

- NAA (*N*-acetylaspartate), 640
- National Birth Defects Prevention Study, 704
- National Center for Health Statistics, 808
- NCS (Neurocritical Care Society), 767, 772, 774, 783, 789
- NEAD (Neurodevelopmental Effects of Antiepileptic Drugs) study, 708
- Neocortical epilepsies
 neuroimaging in, 623, 625, 628–630, 628t, 629f, 630f
 surgical treatment of, 735–736
- Neonatal complications of in utero exposure to antiepileptic drugs, 708–709
- Neonatal epilepsies, 586t
- Neoplastic etiologies of epilepsy, 579t, 580t, 587t.
See also Brain neoplasms
 status epilepticus due to, 769t
- Neural tube defects, antiepileptic drug-induced, 652, 703, 703t, 704, 706
- Neurocardiogenic syncope, 615c–618c, 616f–618f
- Neurocritical Care Society (NCS), 767, 772, 774, 783, 789
- Neurocysticercosis, 580t

Neurodevelopmental effects of antiepileptic drugs, 685, 686c, 694r, 707–708, 709f, 713r–714r

Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study, 708

Neuroimaging, 623–641, 641r–642r. *See also specific imaging modalities*

CT, 624

diffusion tensor imaging and tractography, 639–640, 642r

emergent, 624

indications for, 624

of low-grade tumors, 637f–639f, 638

magnetic resonance spectroscopy, 640

in mesial temporal lobe epilepsy with hippocampal sclerosis, 623, 625, 625f, 626–628, 626f, 627c, 627t

presurgical evaluation, 628, 631t

MRI, 624–626

in neocortical epilepsies, 628–631, 628t, 629f, 630f

PET, 640

in preoperative workup, 731, 733f, 734, 734f

for childhood epilepsy, 676, 676f

in Rasmussen encephalitis, 590f, 624, 639

SPECT, 641

in status epilepticus, 772, 774, 776, 780t

in surgical candidates, 731

in tuberous sclerosis, 637–638, 637f

Neuroinflammation, 573

Neuroleptics. *See* Antipsychotics

Neurologic Disorders Depressive Inventory in Epilepsy, 688

Neurologists, 588

Neuronal ceroid lipofuscinosis, 579t

NeuroPace Responsive Neurostimulation System, 749–751

efficacy of, 751, 751f

implantation of, 750

mechanism of action of, 750, 751f

randomized controlled trial of, 750–751, 751f

Neuropsychological comorbidities, 682–693, 693r–696r

cognitive impairment, 682–687

health-related quality of life, 691–693

psychiatric disorders, 687–691

anxiety disorders, 691

depression, 687–691

psychosis, 691

Neuropsychological testing, in preoperative workup, 732

for childhood epilepsy, 676, 676f

Neurostimulation, 743–754, 754r–755r

deep brain stimulation of anterior nucleus of thalamus, 743, 746–749, 748f

devices for, 743, 744

advantages and disadvantages of, 753

responder rates for, 752–753

responsive, 743, 749–751, 750f, 751f

trigeminal nerve stimulation, 743, 751–752, 753f

vagus nerve stimulation, 743, 744–746, 746t, 747c

Nonepileptic behavioral disorders, 715–727, 727r–729r

nonpsychogenic, 715

psychogenic (*See* Psychogenic nonepileptic events or episodes)

Nonsyndromic epilepsies, 589t, 590–591, 591f, 594

resolution of, 595

North American AED Pregnancy Registry, 704, 706

O

Obese patients, 650

Occipital epilepsy, late onset childhood, 587t

Ohtahara syndrome, 579t, 586t

EEG in, 607, 609t, 674t

treatment choices for, 674t–675t

Oligodendrogliomas, 638, 638f, 736

Oral contraceptives, interaction with antiepileptic drugs, 652, 702

Ornithine transcarbamylase deficiency, 579t

Oroalimentary seizures, 585t

Osteopenia/osteoporosis, antiepileptic drug-induced, 652, 711–712, 711c

Oxcarbazepine

adverse effects of, 646t

cognitive effects of, 684, 693r

efficacy and tolerability of, 643, 648

mechanism of action and metabolism of, 644t

mood-stabilizing effects of, 652

as narrow-spectrum agent, 645, 648t

in pregnancy

pharmacokinetics of, 710, 710t

teratogenicity of, 707t

use in children, 666t–667t

P

Panayiotopoulos syndrome, 586t, 624

EEG in, 674t

treatment choices for, 674t–675t

Panic disorder, 726

Paroxetine, 692c

Paroxysmal movement disorders, 715

PDR (Physicians' Desk Reference), 802, 804r

Pediatric neurologists, 588

Pediatric patients. *See* Childhood epilepsy

Pentobarbital

adverse effects of, 787t, 789

coma induced by, 770c

dosage of, 786t

pharmacokinetics of, 787t

for status epilepticus, 783f, 786t–787t

refractory, 788–789

Perampanel, 645t, 646t

spectrum of activity of, 648t

use in children, 666t–667t

Perimenopausal transition, 700

- Periodic lateralizing discharges (PLDs) on EEG, 613, 613t, 614f
- Periodic patterns on EEG in critically ill and comatose patient, 609, 613, 613t, 614f–615f
- Periventricular nodular heterotopia, on MRI, 635f, 636, 636f
- PET. *See* Positron emission tomography
- Pharmacokinetics of antiepileptic drugs, intrapartum and postpartum, 709–711, 710t, 714r
- Pharmacoresponsive or pharmacoresistant epilepsy, 595, 730–731, 743–744
- Phenobarbital, 606c, 692c
 adverse effects of, 646t, 785t, 802
 depression, 652
 as broad-spectrum agent, 645, 648t
 cognitive effects of, 684, 693r
 combined with valproate, 649, 649t
 dosage of, 784t
 drug interactions with, 652
 hypersensitivity to, 650
 mechanism of action and metabolism of, 644t
 pharmacokinetics of, 710t, 785t
 in pregnancy
 neurodevelopmental outcomes of, 707
 pharmacokinetics of, 710t
 teratogenicity of, 705c, 706f, 707t
 seizures worsened by, 645
 for status epilepticus, 770c, 778, 781t, 784t–785t
 use in children, 668t–669t
- Phenytoin, 606c
 adverse effects of, 646t, 785t, 802
 during breast-feeding, 685
 cognitive effects of, 684, 693r
 combined with carbamazepine, 649, 649t
 dosage of, 784t
 drug interactions with, 652
 hypersensitivity to, 650
 mechanism of action and metabolism of, 644t
 pharmacokinetics of, 710, 710t, 785t
 in pregnancy, 685, 704
 neurodevelopmental effects of, 707, 708, 709f
 pharmacokinetics of, 710, 710t
 teratogenicity of, 704, 707t
 spectrum of activity of, 645, 648t
 for status epilepticus, 770c, 775c, 778, 781t, 783f, 784t–785t
 use in children, 668t–669t
- Photic stimulation, EEG with, 601, 602f
- Photoconvulsive response, 601
- Photoparoxysmal responses, 601, 602f
- Physicians' Desk Reference (PDR)*, 802, 804r
- Plasmapheresis
 for childhood epilepsy, 679
 for status epilepticus, 788t–789t
- PLDs (periodic lateralizing discharges) on EEG, 613, 613t, 614f
- PNEE. *See* Psychogenic nonepileptic events or episodes
- Polycystic ovarian syndrome, 700, 713r
- Polymicrogyria, on MRI, 634–636, 634f, 635f
- Positron emission tomography (PET), 623, 640, 642r, 731
 18F-fluorodeoxyglucose, 623, 640, 642r
 of focal cortical dysplasia, 738f
 in mesial temporal lobe epilepsy, 640
 in neocortical epilepsies, 628t
 in preoperative workup, 734, 734f
 for childhood epilepsy, 676
- Posttraumatic stress disorder (PTSD), 688, 726
- Pregabalin
 adverse effects of, 646t, 787t
 weight gain, 650
 dosage of, 786t
 efficacy of, 648
 hypersensitivity to, 650
 mechanism of action and metabolism of, 644t
 as narrow-spectrum agent, 645, 648t
 pharmacokinetics of, 787t
 in renal disease, 650
 for status epilepticus, 786t–787t
 use in children, 668t–669t
- Pregnancy, 702–711, 713r–714r
 antiepileptic drugs in, 652–653, 653c, 655r, 685, 686c, 702–711 (*See also specific drugs*)
 neonatal complications of, 708–709
 neurodevelopmental effects of, 685, 686c, 694r, 707–708, 709f
 pharmacokinetics of, 709–711, 710t
 teratogenicity of, 652, 653c, 702, 703, 703t
 monotherapies, 703–706, 705c, 706f, 707t
 polytherapy, 706–707
 effect on seizure frequency, 709
 seizure risk to fetus, 709
- Premature ovarian failure, 700
- Presentation of seizures, 573–576, 575t, 573571
- Primidone
 as broad-spectrum agent, 648t
 drug interactions with, 652
 mechanism of action and metabolism of, 644t
 pharmacokinetics in pregnancy, 710t
- Profile of Mood States, 684
- Progesterone
 during menstrual cycle, 698, 699f
 during perimenopausal transition, 700
- Progesterone lozenges, for catamenial epilepsy, 699–700
- Propofol
 adverse effects of, 787t, 789
 dosage of, 786t
 pharmacokinetics of, 787t
 for status epilepticus, 770c, 781t, 783f, 786t–787t
 refractory, 788–789
- Propranolol, interaction with antiepileptic drugs, 652
- Psychiatric disorders, 687–691, 694r–696r
 antiepileptic drugs in, 652
 anxiety disorders, 691

- depression and suicidality, 687–691, 690c, 804
 impact on health-related quality of life, 692–693
 psychogenic nonepileptic events or episodes
 and, 722–723, 726
 psychosis, 691
- Psychiatric medications, interaction with
 antiepileptic drugs, 652
- Psychic-experiential features, 586t
- Psychogenic nonepileptic events or episodes
 (PNEE), 622r, 715–727, 727r–729r
 border zone of, 725–726
 in children, 725
 confirming diagnosis of, 717–720
 routine or ambulatory EEG, 717
 video-EEG monitoring, 715, 717–720, 718t,
 726
 inductions for, 719
 pitfalls of, 719–720
 short-term outpatient, with activation, 719
- depression and, 688
- difficult and special issues in diagnosis of,
 720–722
 PNEE in unexpected setting, 722
 previous abnormal EEG, 720–722, 721c, 721f
- on EEG, 619–620
 management of, 715, 724–725
 role of mental health professional in,
 724–725
 role of neurologist in, 724
- a more general perspective on, 726
 prognosis for, 723–724
 psychopathology and, 722–723, 726
 routine and ambulatory EEG in, 717
 suspecting diagnosis of, 716–717, 716t
 terminology for, 715–716
 websites for information on, 726–727
- Psychosis and epilepsy, 691, 696r
 paradoxical normalization and, 691, 692c
- PTSD (posttraumatic stress disorder), 688, 726
- Pyridoxine-deficient epilepsy, 579t, 679
- Pyruvate dehydrogenase deficiency, 579t
 dietary therapy for, 678–679, 759
- Q**
- Quality of life, health-related (HRQOL), 691–693,
 694r, 696r
 relation to antiepileptic drug toxicity, 693
 relation to mood, 692–693
 relation to seizure freedom and epilepsy
 surgery, 691–692
- Quetiapine, 691
- R**
- Radiosurgery, 739t, 742r
 for arteriovenous malformations, 737, 742r
 for hippocampal epilepsy, 735
 for hypothalamic hamartoma, 737
- Rapid Anticonvulsant Medication Prior to Arrival
 Trial (RAMPART), 767, 777
- Rasmussen syndrome, 580t, 587t, 588, 597r
 immunomodulatory therapies for, 679
 MRI in, 590f, 624
 surgical treatment in, 738
- Reflex epilepsies, 587t
- Renal disease, antiepileptic drugs in, 650, 778
- Reproductive function of women with epilepsy,
 700–702. *See also* Pregnancy
 antiepileptic drug effects on reproductive
 hormones, 700–701, 701t
 fertility and childbirth rates, 701–702
- Responsive neurostimulation system (RNS), 743,
 749–751, 750f, 751f
 efficacy of, 751, 751f
 implantation of, 750
 mechanism of action of, 750, 751f
 randomized controlled trial of, 750–751, 751f
 responder rate for, 752
- Retigabine. *See* Ezogabine
- Rett syndrome, dietary therapy for, 679, 759
- Rhythmic midtemporal theta of drowsiness,
 607–608, 609t, 610f
- Rhythmic temporal delta activity on EEG, 607,
 608f
- Ring chromosome 20, 579t
- Risperidone, 692c
- Rituximab, for childhood epilepsy, 679
- RNS. *See* Responsive neurostimulation system
- Rufinamide
 adverse effects of, 646t
 for Lennox-Gastaut syndrome, 645
 mechanism of action and metabolism of, 645t
 as narrow-spectrum agent, 648t
 use in children, 668t–669t
- S**
- Scalp EEG monitoring, 619–620
- Schizencephaly, on MRI, 633–634, 634f
- SCNA1* gene mutations, 576c, 589t, 596r
 testing for, 797–799
- Seizures. *See also* Epilepsy
 age at onset of, 580, 586t–587t, 674t
 classification of, 571–595, 595r–597r
 etiologies/causes of, 571, 573, 574t, 578,
 579t–580t
 focal, 571, 573–576, 575t, 578, 581t
 generalized, 571, 573–576, 575t, 578, 581t
 induced by antiepileptic drug withdrawal, 650
 mode of onset and presentation of, 571,
 573–576, 574t
 nonepileptic mimics of (*See* Psychogenic
 nonepileptic events or episodes)
 patient populations likely to be overdiagnosed
 with, 722
 pediatric (*See* Childhood epilepsy)
 psychogenic nonepileptic, 619–620
 types of, 578–580, 581t, 582t, 583f, 584t–586t
 unprovoked, 594
- Selective serotonin reuptake inhibitors (SSRIs)

- for anxiety disorders, 691
- for depression, 689–690
- Self-limited epilepsy, 594–595
- Sertraline, 690
- Sex steroid hormones
 - effects of antiepileptic drugs on, 700–701, 701t
 - interactions between epilepsy, antiepileptic drugs and, 697, 698f
- Shuddering attacks, 715
- Sialidosis, 579t
- Single-photon emission computed tomography (SPECT), 623, 641, 642r, 731
 - depression related to findings on, 687
 - to determine surgical candidacy, 732c, 732f
 - in focal cortical dysplasia, 738c
 - in hippocampal sclerosis, 631t
 - in mesial temporal lobe epilepsy, 641
 - in neocortical epilepsies, 628t
 - in preoperative workup, 732f, 734
 - for childhood epilepsy, 676, 676f
 - radiotracers for, 641, 734
- SIRPIDs (stimulus-induced, rhythmic, periodic, or ictal discharges) on EEG, 613, 613t
- SLC2A1* gene mutations, 589t
- Sleep deprivation, EEG with, 601, 621r
- Social phobia, 726
- Somatoform disorders, 722–723, 725, 726
- Special syndromes, 594
- SPECT. *See* Single-photon emission computed tomography
- SREDA (subclinical rhythmic electrographic discharges of adults) on EEG, 608, 609t, 612f
- SSRIs (selective serotonin reuptake inhibitors)
 - for anxiety disorders, 691
 - for depression in epilepsy, 689–690
- Staring spells, 660c, 725
- Status epilepticus, 594, 767–792, 792r–794r
 - in children, 767
 - classification of, 767, 768t
 - cryptogenic new-onset, 768, 770c, 771f
 - definition of, 767, 780t
 - diagnostic implication of subtypes of, 772t
 - dietary therapy for, 679, 759, 761c, 766r
 - in Dravet syndrome, 576c
 - EEG in, 608–613, 773–774
 - continuous EEG monitoring, 618, 622r, 768, 774, 778c, 779f
 - convulsive, *Mycoplasma pneumoniae*-associated, 771f
 - nonconvulsive, 775f
 - periodic patterns, 609, 613, 613t, 614f–615f
 - progressive sequence of changes, 608–609, 621r
 - epidemiology of, 767–768
 - etiologies of, 768, 769t
 - generalized convulsive, 608
 - clinical features of, 768–769, 770c
 - EEG in, 771f
 - neuroimaging in, 772
 - physiologic changes in, 769, 773f
 - treatment of, 776–791, 792
 - failure of second-line therapy and refractory status epilepticus, 783, 788–790
 - first-line therapy, 776–777
 - general aspects of, 776
 - malignant and super-refractory status epilepticus, 790
 - medications, 776–783, 784t–789t
 - nonpharmacologic approaches, 790, 790t
 - second-line therapy, 777–783
 - induced by antiepileptic drug withdrawal, 650
 - management of, 772–776
 - EEG, 773–774
 - evidence and guidelines for, 772, 780t–782t, 783f
 - laboratory tests, 772–773
 - lumbar puncture, 776
 - neuroimaging, 772, 774, 776
 - mortality due to, 791
 - myoclonic, after cardiac arrest, 791
 - nonconvulsive, 608, 767–768
 - absence, 608
 - clinical features of, 769–770, 774t, 775c
 - in comatose patients, 608, 618, 622r
 - continuous EEG monitoring in, 618, 622r, 768, 778c, 779f
 - diagnosis in critically ill patients, 770, 772, 778c, 779f
 - antiepileptic drug trial for, 770, 777t
 - criteria for, 776t
 - partial complex, 608
 - prolonged, neuropathologic changes after, 791
 - risk factors for, 767–768
 - treatment of, 791, 792
 - nonencephalitic febrile, 580t
 - outcome of, 791
 - peak ages for, 767
 - refractory
 - after cardiac arrest, 791
 - definition of, 783
 - incidence and predictors of, 783
 - treatment of, 783, 788–790, 791
- Steroid hormones, interaction with antiepileptic drugs, 652
- Stevens-Johnson syndrome, 649, 672, 706c
 - HLA-B*1502* allele and risk for, 672, 804, 805r
- Stimulus-induced, rhythmic, periodic, or ictal discharges (SIRPIDs) on EEG, 613, 613t
- Stiripentol, use in children, 668t–669t
- Stroke, 587t
 - nonconvulsive status epilepticus and, 618
 - with psychogenic nonepileptic events or episodes, 722
 - status epilepticus due to, 769t
 - surgical treatment of epilepsy due to, 737
- Structural-metabolic epilepsies, 571, 573, 574t, 578, 587t, 590f
 - nonsyndromic, 590–591, 594
- Sturge-Weber syndrome, 587t, 603t, 737, 738
 - dietary therapy for, 759

- Subclinical rhythmic electrographic discharges of adults (SREDA) on EEG, 608, 609t, 612f
- Subcortical laminar heterotopia, on MRI, 635f, 636
- Subcortical structures, 573
- Subdural empyema, 580t
- Subdural grid electrodes, 620
- Suicidality, 688–689, 804
- Surgical treatment, 730–740, 740r–742r. *See also* Radiosurgery
- of childhood epilepsy, 673, 676–678
 - candidates for, 673, 676
 - estimating potential deficits after, 676, 677
 - outcome of, 677–678
 - preoperative workup for, 676–677, 676f, 677f
 - procedures for, 677
 - cognitive effects of, 685–686, 694r, 732
 - continuation of antiepileptic drugs after, 740
 - contraindications to, 731, 732c
 - epilepsies with implications for, 582, 587t, 588, 735–740
 - corpus callosotomy, 738–740
 - epilepsy due to atrophic lesions, 737–738
 - epilepsy due to developmental abnormalities, 593t, 737, 737f–739f, 738c
 - epilepsy due to tumors, 736–737, 736f
 - epilepsy due to vascular malformations, 737
 - hemispheric syndromes, 738
 - mesial temporal lobe epilepsy, 730, 735, 736c, 736f
 - neocortical epilepsy, 735–736
 - for focal cortical dysplasia, type IIB, 577c
 - focal seizures without indication for, 576, 576c
 - goal of, 740
 - health-related quality of life related to seizure freedom and, 691–692
 - for hippocampal sclerosis, 627c
 - ongoing and future trends in, 739t, 740
 - outcomes of, 740, 743–744
 - preoperative workup for, 731–735
 - functional localization, 734–735
 - further noninvasive assessment, 734, 734f
 - initial evaluation, 731–732, 733f
 - invasive video-EEG monitoring, 731, 733f, 734, 739f
 - in Rasmussen syndrome, 590t
 - reasons for, 730
 - selecting candidates for, 730–731, 753
 - in status epilepticus, 790t
 - in tuberous sclerosis complex, 737
 - in West syndrome, 593t
- Syncope
- differentiating seizures from, 656–657, 715
 - neurocardiogenic, 615c–618c, 616f–618f
- T**
- Temporal lobe epilepsy
- autosomal dominant lateral, 579t, 587t
 - cognitive impairment in, 683
 - surgery effects on, 685–686
 - familial, 587t, 597r
 - mesial, 588
 - familial, 597r
 - with hippocampal sclerosis, 587t, 625f, 626f, 627c, 627t
 - magnetic resonance spectroscopy in, 640
 - with mesial temporal sclerosis, 735, 736c
 - MRI in, 623, 625, 625f, 626f, 627c, 627t
 - positron emission tomography in, 640
 - single-photon emission computed tomography in, 641
 - surgical treatment of, 730, 735, 736c
- Temporal lobectomy, 730, 735
- Teratogenicity of antiepileptic drugs, 652, 655r, 702, 703–707, 703t
- monotherapies, 703–706, 705c, 706f, 707t
 - polytherapy, 706–707
- Thiopental, for status epilepticus, 781t, 788–789
- Thyrototoxicosis, 600
- Tiagabine
- adverse effects of, 646t
 - efficacy of, 648
 - mechanism of action and metabolism of, 644t
 - as narrow-spectrum agent, 645, 648t
 - use in children, 668t–669t
- TNS. *See* Trigeminal nerve stimulation
- Tonic seizures, 581t, 584t
- differential diagnosis of, 582t
 - EEG in, 582t, 583f
- Topiramate
- adverse effects of, 646t, 787t, 804, 805r
 - depression, 652
 - psychosis, 691
 - as broad-spectrum agent, 645, 648t
 - cognitive effects of, 684, 693r
 - combined with other antiepileptic drugs, 649, 649t
 - dosage of, 786t
 - efficacy and tolerability of, 643, 648
 - mechanism of action and metabolism of, 644t
 - pharmacokinetics of, 787t
 - in pregnancy, 652, 653c, 655r, 704
 - teratogenicity of, 652, 653c, 704, 707t
 - for status epilepticus, 786t–787t
 - use in children, 670t–671t
 - weight loss induced by, 650
- Tramadol, EEG abnormalities induced by, 600
- Traumatic brain injury, 580t, 587t, 603t
- nonconvulsive status epilepticus due to, 618, 769t, 778c, 779f
 - with psychogenic nonepileptic events or episodes, 722
 - surgical treatment of epilepsy due to, 737–738
- Tricyclic antidepressants, 690, 692c
- Trigeminal nerve stimulation (TNS), 743, 751–752, 755r
- adverse effects of, 752
 - basic science and mechanism of action of, 752
 - responder rate for, 752, 753f

Triphasic waves on EEG, 602, 603t, 604, 604f, 621r
 Tuberculosis, 580t
 Tuberos sclerosis complex, 578, 579t, 587t
 dietary therapy for, 679, 759, 765r
 neuroimaging in, 637–638, 637f
 surgical treatment of, 737
 vagus nerve stimulation in, 678
 Types of seizures, 578–580, 581t, 582t, 583f
 extended terminology for, 584t–586t

U

UK Epilepsy and Pregnancy Register, 704
 Unknown causes, epilepsy due to, 571, 573, 574t, 588t
 Unverricht disease, 579t
 Uremia, 600

V

VA Cooperative Geriatric Epilepsy Study, 684
 Vagus nerve stimulation (VNS), 743, 744–746, 754r
 advantages of, 753
 cardiac effects of, 744
 in childhood epilepsy, 593t, 678, 681r
 cognitive effects of, 686–687
 complications of, 678
 for depression, 745
 in drug-resistant epilepsy, 731
 efficacy of, 745, 747c
 electrode placement for, 744
 ketogenic diet and, 759
 parameters and programming settings for, 745, 746t
 responder rate for, 752
 transcutaneous, 743, 745–746
 Valproate
 for absence seizures with perioral myoclonia, 606c–607c
 adverse effects of, 646t, 780, 785t, 802, 805r
 hepatotoxicity, 780, 801c
 monitoring for, 801c
 polycystic ovarian syndrome, 700
 weight gain, 650
 during breast-feeding, 685
 as broad-spectrum agent, 645, 648t
 for children, 779–780
 cognitive effects of, 684, 693r
 combined with lamotrigine, 649, 649t, 653c
 combined with phenobarbital, 649, 649t
 dosage of, 784t
 drug interactions with, 652
 efficacy and tolerability of, 648, 654r
 in hepatic disease, 650
 hypersensitivity to, 650
 indications for, 647
 mechanism of action and metabolism of, 644t
 mood-stabilizing effects of, 652

 pharmacokinetics of, 785t
 in pregnancy, 652–653, 685, 686c, 704, 705c
 neurodevelopmental effects of, 707, 708, 709f
 pharmacokinetics of, 710t
 teratogenicity of, 652, 653c, 704, 705c, 706–707, 706f, 707t, 708f
 in status epilepticus, 770c, 775c, 778–780, 783, 783f, 784t–785t
 for diagnosis of nonconvulsive status epilepticus, 777t
 use in children, 670t–671t
 Venlafaxine, 690
 Versive seizures, 584t
 Video-EEG monitoring, 598, 619–620, 622r, 731
 in diagnosis of psychogenic nonepileptic events or episodes, 715, 717–720, 718t, 726, 727r–729r
 inductions for, 719
 pitfalls of, 719–720
 short-term outpatient, with activation, 719
 invasive monitoring, 620
 in preoperative workup, 731, 733f, 734, 739f
 for childhood epilepsy, 676, 676f
 scalp EEG monitoring, 619–620
 for seizure confirmation in children, 657
 Vigabatrin
 adverse effects of, 646t, 787t, 804, 805r
 depression, 652
 dosage of, 786t
 efficacy of, 648
 for infantile spasms, 577c, 654r
 mechanism of action and metabolism of, 644t
 as narrow-spectrum agent, 645, 648t
 pharmacokinetics of, 787t
 for status epilepticus, 786t–787t
 use in children, 670t–671t
 Vitamin D level, antiepileptic drug effects on, 652, 711c, 712, 714r
 VNS. *See* Vagus nerve stimulation
 Vocal seizures, 585t

W

Walker-Warburg syndrome, 579t
 Warfarin, interaction with antiepileptic drugs, 652
 Weight changes, antiepileptic drug-induced, 650
 West syndrome, 576, 579t, 586t, 590, 591f, 594.
 See also Infantile spasms
 classification and characterization of, 593t
 dietary therapy for, 759
 EEG in, 603t, 607, 609t, 674t
 Wicket spikes on EEG, 607, 608, 609t, 611f
 Women with epilepsy, 697–712, 712r–714r
 antiepileptic drugs for, 652–653
 during breast-feeding, 684–685, 694r, 705c
 in pregnancy, 652–653, 653c, 655r, 685, 686c

tridirectional interactions between epilepsy,
sex steroid hormones and, 697, 698f
bone health of, 711–712, 711c
catamenial epilepsy, 697–700
criteria for, 698
definition of, 697
patterns of, 698, 699f
treatment options for, 698–700
contraception for, 702
during perimenopause and menopause, 700
pregnancy in, 702–711 (*See also* Pregnancy)
reproductive function of, 700–702
antiepileptic drug effects on reproductive
hormones, 700–701, 701t
fertility and childbirth rates, 701–702

Z

Zonisamide

adverse effects of, 646t
psychosis, 691
teratogenicity, 707t
as broad-spectrum agent, 645, 648t
cognitive effects of, 684, 694r
combined with other antiepileptic drugs, 649,
649t
efficacy and tolerability of, 643, 648
mechanism of action and metabolism of,
645t
use in children, 670t–671t
weight loss induced by, 650